Epstein-Barr virus in children with classical Hodgkin’s lymphoma

Cover Page

Cite item

Full Text

Abstract

Classical Hodgkin's lymphoma (cHL) is one of the many malignant tumors associated with the Epstein-Barr virus (EBV). It is shown that EBV-positive cases of cHL are distributed with different frequencies among all cases of the disease. The frequency of EBV-positive cases of cHL is influenced by the demographic characteristics of the studied population and other factors. Russia belongs to geographical regions with a low incidence of this form of tumor. The aim of the study was to estimate the humoral response to EBV and the level of viral DNA in the blood plasma of children with cHL and to evaluate the significance of both EBV markers for clinical manifestations of the disease. The data obtained have shown that the level of EBV persistence in children with cHL practically does not differ from that in healthy children, however, the activity of the humoral response to EBV was significantly lower. The study of the composition of the elements of the leukocyte germ, responsible for cellular and humoral immunity, did not make it possible to explain the observed phenomenon. In particular, the number of circulating leukocytes in the patients' blood before the treatment corresponded to normal values, but it turned out to be below the normal values after the treatment. Conversely, the percentage of lymphocytes in patients before treatment turned out to be lower than normal values, but it reached normal values after the treatment. The percentage of neutrophils and monocytes in patients before and after the treatment was almost the same as in healthy individuals. The data obtained suggest that the reduced humoral response in patients with cHL is not associated with the altered composition of the leukocyte germ cells, but due to their reduced functional activity. The search for copies of virus DNA in plasma and oral cavity swabs made it possible to detect them only in some patients before the therapy and to state their complete absence after the treatment. Dynamic observation of the EBV DNA concentration in blood plasma and humoral response to EBV in 3 patients showed increased values viral DNA copies before treatment, and their decrease to zero after successful therapy, while antibody titers remained at the same level and did not reflected the clinical state of patients. It can be assumed that the increased concentration of plasma viral DNA detected in cHD patients can become a marker that allows indirectly estimating the degree of minimal residual disease and the probability of recurrence of the disease.

About the authors

I V Botezatu

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

канд. биол. наук, науч. сотр. лаб. биохимии опухолей 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

T T Valiev

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

канд. мед. наук, ст. науч. сотр. отд. химиотерапии гемобластозов 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

T E Dushenkina

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

лаб.-исследователь лаб. вирусного канцерогенеза 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

K V Smirnova

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

канд. биол. наук, зав. лаб. вирусного канцерогенеза 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

R S Ravshanova

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

канд. мед наук, ст. науч. сотр. отд. химиотерапии гемобластозов 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

D M Maksimovich

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

канд. матем. наук, ст. науч. сотр. отд. эпидемологии опухолей 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

A V Likhtenstein

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

д-р. биол. наук, вед. науч. сотр. лаб. биохимии опухолей 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

V E Gurtsevich

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Email: vlad-88@yandex.ru
д-р. мед. наук, вед. науч. сотр. лаб. вирусного канцерогенеза 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

A V Popa

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

д-р. мед. наук, зав. отд. химиотерапии гемобластозов 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

N B Senyuta

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

канд. мед. наук, вед. науч. сотр. лаб. вирусного канцерогенеза 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

References

  1. Rickinson A.B, Lane P.J. Epstein-Barr virus: Co-opting B-cell memory and migration. Curr Biol 2000; 10: R120-R123.
  2. Abbott R.J, Pachnio A, Pedroza-Pacheco I et al. Asymptomatic Primary Infection with Epstein-Barr Virus: Observations on Young Adult Cases. J Virol 2017; 91 (21): e00382-17.
  3. Kang M.S, Kieff E. Epstein-Barr virus latent genes. Exp Mol Med 2015; 47 (1): e131.
  4. Gallo A, Vella S, Miele M et al. Global profiling of viral and cellular non-coding RNAs in Epstein-Barr virus-induced lymphoblastoid cell lines and released exosome cargos. Cancer Lett 2017; 388: 334-43.
  5. Piedade D, Azevedo-Pereira J.M. The Role of microRNAs in the Pathogenesis of Herpesvirus Infection. Viruses 2016; 8 (6). pii: E156. doi: 10.3390/v8060156
  6. Young L.S, Murray P.G. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 2003; 22: 5108-21.
  7. Alexander F.E, Jarrett R.F, Lawrence D et al. Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other. Br J Cancer 2000; 82:1117-21.
  8. Mueller N, Evans A, Harris N.L et al. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med 1989; 320: 689-95.
  9. Anagnostopoulos I, Herbst H, Niedobitek G et al. Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization. Blood 1989; 74: 810-6.
  10. Tanyildiz H.G, Yildiz I, Bassullu N et al. The Role of Epstein-Barr Virus LMP-1 Immunohistochemical Staining in Childhood Hodgkin Lymphoma. Iran J Pediatr 2015; 25: e2359.
  11. Iwakiri D, Takada K. Role of EBERs in the pathogenesis of EBV infection. Adv Cancer Res 2010; 107: 119-36.
  12. Vockerodt M, Wei W, Nagy E et al. Suppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle. J Pathol 2013; 230: 399-409.
  13. Anderson L.J, Longnecker R. Epstein-Barr virus latent membrane protein 2A exploits Notch1 to alter B-cell identity in vivo. Blood 2009; 113: 108-16.
  14. Soni V, Cahir-McFarland E, Kieff E. LMP1 TRAFficking activates growth and survival pathways. Adv Exp Med Biol 2007; 597: 173-87.
  15. Eliopoulos A.G, Young L.S. LMP1 structure and signal transduction. Semin Cancer Biol 2001; 11: 435-44.
  16. Wang F, Gregory C, Sample C et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 1990; 64: 2309-18.
  17. Henderson S, Rowe M, Gregory C et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991; 65: 1107-15.
  18. Laherty C.D, Hu H.M, Opipari A.W et al. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem 1992; 267: 24157-60.
  19. Uchida J, Yasui T, Takaoka-Shichijo Y et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 1999; 286: 300-3.
  20. Schwarzer R, Dorken B, Jundt F. Notch is an essential upstream regulator of NF-kappaB and is relevant for survival of Hodgkin and Reed-Sternberg cells. Leukemia 2012; 26: 806-13.
  21. Khan G, Miyashita E.M, Yang B et al. Is EBV persistence in vivo a model for B cell homeostasis? Immunity 1996; 5: 173-9.
  22. Alexander F.E, McKinney P.A, Williams J et al. Epidemiological evidence for the 'two-disease hypothesis' in Hodgkin's disease. Int J Epidemiol 1991; 20: 354-61.
  23. Levin L.I, Chang E.T, Ambinder R.F et al. Atypical prediagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin lymphoma. Blood 2012; 120: 3750-5.
  24. Henle W, Henle G, Andersson J et al. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc Natl Acad Sci U. S. A 1987; 84: 570-4.
  25. Chang E.T, Zheng T, Lennette E.T. et al. Heterogeneity of risk factors and antibody profiles in epstein-barr virus genome-positive and -negative hodgkin lymphoma. J Infect Dis 2004; 189: 2271-81.
  26. Diepstra A, Niens M, Vellenga E et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. Lancet 2005; 365: 2216-24.
  27. Huang X, Kushekhar K, Nolte I et al. HLA associations in classical Hodgkin lymphoma: EBV status matters. PLoS One 2012; 7: e39986.
  28. Niens M, Jarrett R.F, Hepkema B et al. HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Blood 2007; 110: 3310-5.
  29. Urayama K.Y, Jarrett R.F, Hjalgrim H et al. Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. J Natl Cancer Inst 2012; 104: 240-53.
  30. Glaser S.L, Lin R.J, Stewart S.L. et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer 1997; 70: 375-82.
  31. Jarrett A.F, Armstrong A.A, Alexander E. Epidemiology of EBV and Hodgkin's lymphoma. Ann Oncol 1996; 7 (4): 5-10.
  32. Jarrett R.F, Gallagher A, Jones D.B et al. Detection of Epstein-Barr virus genomes in Hodgkin's disease: relation to age. J Clin Pathol 1991; 44: 844-8.
  33. Детская онкология. Национальное руководство. Под ред. М.Д.Алиева, В.Г.Полякова, Г.Л.Менткевича, С.А.Маяковой. М.: Издательская группа РОНЦ, 2012
  34. Stein H, Delsol G, Pileri S.A et al. Classical Hodgkin lymphoma, introduction. In: Swerdlow S.H, Campo E, Harris N.L et al. (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, 2008.
  35. Botezatu I.V, Kondratova V.N, Shelepov V.P et al. DNA melting analysis: application of the "open tube" format for detection of mutant KRAS. Anal Biochem 2011; 419: 302-8.
  36. Gallagher A, Perry J, Freeland J et al. Hodgkin lymphoma and Epstein-Barr virus (EBV): no evidence to support hit-and-run mechanism in cases classified as non-EBV-associated. Int J Cancer 2003; 104: 624-30.

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies